Drug Trial Radar · NCT05563220
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
435
Planned (sponsor's estimate)
Start
Jan 24, 2023
Primary completion
Dec 27, 2026
Study completion Dec 28, 2028
Sponsor
- Lead sponsor
- Stemline Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, Phase 1b/2 trial in participants with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) advanced/metastatic breast cancer. The phase 1b part of the trial will determine the recommended Phase 2 dose (RP2D) of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, capivasertib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations.
Conditions
- Breast Cancer
- Metastatic Breast Cancer
Interventions
ElacestrantDrug
Elacestrant 86 mg, 172 mg, 258 mg or 345 mg once daily in cycles of 28 days
AlpelisibDrug
Alpelisib 150 mg or 250 mg once daily in cycles of 28 days
EverolimusDrug
Everolimus 5 mg, 7.5 mg, or 10 mg once daily in cycles of 28 days
RibociclibDrug
Ribociclib 400 mg or 600 mg once daily for 21 days followed by 7 days off in cycles of 28 days
PalbociclibDrug
Palbociclib 100 mg or 125 mg once daily for 21 days followed by 7 days off in cycles of 28 days
CapivasertibDrug
Capivasertib 200 mg or 320 mg or 400 mg twice daily for 4 days on, 3 days off in cycles of 28 days
AbemaciclibDrug
Abemaciclib 100 mg or 150 mg twice daily in cycles of 28 consecutive days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with DLTs Observed During the First CycleTime frame: 28 days
- Progression-free SurvivalTime frame: 6 months
Locations
83 sites in 13 countries. Site status is shown where the registry gives one.
Dothan Hematology and Oncology
Dothan, Alabama
Mayo Clinic - Arizona
Phoenix, Arizona
Highlands Oncology Group
Springdale, Arkansas
City of Hope National Medical Center
Duarte, California
OPN Healthcare (Los Alamitos Location)
Los Alamitos, California
Cedars Sinai
Los Angeles, California
UCLA UCLA Hem/Onc - Clinical Research Unit
Los Angeles, California
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California
TOI Clinical Research
Whittier, California
Rocky Mountain Cancer Centers
Lone Tree, Colorado
George Washington Cancer Center
Washington D.C., District of Columbia
Advent Health (Florida Hospital) - Altamonte Springs
Altamonte Springs, Florida
Mayo Clinic - Jacksonville
Jacksonville, Florida
Northwestern Feinberg Scholl of Medicine Prentice Women's Hospital
Chicago, Illinois
MD Alliance for Multispecialty Research, LLC
Merriam, Kansas
Johns Hopkins School of Medicine
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan
Mayo Clinic - Rochester
Rochester, Minnesota
Washington University School of Medicine in St. Louis
St Louis, Missouri
Astera Cancer Care
East Brunswick, New Jersey
Summit Medical Group
Florham Park, New Jersey
Cooperman Barnabas Medical Center
New Brunswick, New Jersey
NYU Langone Health
New York, New York
W&IH of RI Breast Health Center of Women and Infants Hospital of Rhode Island
Providence, Rhode Island
Sarah Cannon Research Institute / Tennessee Oncology
Nashville, Tennessee
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas
MD Anderson Cancer Center Texas
Houston, Texas
UT Health San Antonio
San Antonio, Texas
Virginia Cancer Specialists
Fairfax, Virginia
Virginia Oncology Associates
Norfolk, Virginia
Cancer Care Northwest
Spokane Valley, Washington
Northwest Medical Specialties (Nwms) - Puyallup - Medical Oncology (Rainier Hematology-Oncology)/Exigent Research Network; LLC
Tacoma, Washington
University of WI - Carbone Cancer Center (Phase II only)
Madison, Wisconsin
Centro Medico Austral
Buenos Aires, Argentina
Cemaic - Centro De Especialidades Medicas Ambulatorias E Investigacion Clinica
Córdoba, Argentina
Centro Oncologico Riojano Integral (Cori)
La Rioja, Argentina
Macquarie University
Sydney, Australia
Institut Jules Bordet
Anderlecht, Belgium
Showing 40 of 83 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.